Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
QkjVDSZcwNVJFdNw
Listen
